Alivus Life Sciences board meeting on May 14, 2026 to approve audited financial results for Q4 and FY ending March 31, 2026.
Board will consider recommending dividend for FY 2025-26 on equity shares.
Trading window closed from April 1 to May 16, 2026 for designated persons ahead of results.